Beacon Pharmaceuticals PLC
Abemaciclib Cancer (oncology)
Originator: Verzenio · Eli Lilly and Company (Lilly USA, LLC)
| Brand | Strength | Form |
|---|---|---|
| Abeza | 150 mg and 200 mg tablets | — |
| Abeza | 150 mg | Tablet |
| Abeza | 200 mg | Tablet |
Adalimumab Immunology & rheumatology
Originator: Humira · AbbVie (originally developed and marketed by Abbott Laboratories; initial U.S. approval 2002)
| Brand | Strength | Form |
|---|---|---|
| Adali | 40 mg/0.8 ml | SC Injection |
Baricitinib Immunology & rheumatology
Originator: Olumiant · Eli Lilly and Company (co-developed with Incyte; initial U.S. approval 2018)
| Brand | Strength | Form |
|---|---|---|
| Barinez | 2 mg | Tablet |
Bevacizumab Cancer (oncology)
Originator: Avastin · Genentech, Inc. / F. Hoffmann-La Roche Ltd
| Brand | Strength | Form |
|---|---|---|
| Bevastim | 100 mg/4 mL and 400 mg/16 mL | — |
| Bevastim | 100 mg/4 ml | IV Infusion |
| Bevastim | 400 mg/16 ml | IV Infusion |
Crizotinib Cancer (oncology)
Originator: Xalkori · Pfizer
| Brand | Strength | Form |
|---|---|---|
| Crizonix | 250 mg capsule | — |
| Alkriz | 250 mg capsule | — |
| Alkriz | 250 mg | Capsule |
Dapagliflozin Diabetes & metabolic
Originator: Forxiga · AstraZeneca (originally developed with Bristol-Myers Squibb)
| Brand | Strength | Form |
|---|---|---|
| Dapawin | 5 mg | — |
Empagliflozin Diabetes & metabolic
Originator: Jardiance · Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH)
| Brand | Strength | Form |
|---|---|---|
| Sinjard | 10 mg, 25 mg | — |
| Sinjard | 25 mg | Tablet |
| Sinjard | 10 mg | Tablet |
Ibrutinib Cancer (oncology)
Originator: Imbruvica · Pharmacyclics LLC (an AbbVie company) and Janssen Biotech, Inc. (Johnson & Johnson) - developed and commercialised jointly; US distributor of record: Pharmacyclics LLC
| Brand | Strength | Form |
|---|---|---|
| Ibrucon | 140 mg capsule | — |
| Ibrucon | 140 mg | Capsule |
Linagliptin Diabetes & metabolic
Originator: Tradjenta · Boehringer Ingelheim (marketed in the US by Boehringer Ingelheim Pharmaceuticals, Inc.; co-promoted with Eli Lilly in several markets)
| Brand | Strength | Form |
|---|---|---|
| Glipxen | 5 mg tablet | — |
| Glipxen | 5 mg | Tablet |
Lorlatinib Cancer (oncology)
Originator: Lorbrena · Pfizer Inc.
| Brand | Strength | Form |
|---|---|---|
| Loranix | 100 mg tablet | — |
| Loranix | 100 mg | Tablet |
Niraparib Cancer (oncology)
Originator: Zejula · GlaxoSmithKline (GSK); originally developed by Tesaro (Tesaro UK Limited)
| Brand | Strength | Form |
|---|---|---|
| Niraparix (also listed as Nirova on MedEx) | 100 mg capsule | — |
| Nirova | 100 mg | Capsule |
Olaparib Cancer (oncology)
Originator: Lynparza · AstraZeneca (distributed by AstraZeneca Pharmaceuticals LP); developed and commercialised in collaboration with Merck (MSD outside the US and Canada)
| Brand | Strength | Form |
|---|---|---|
| Olapar | 100 mg and 150 mg tablets | — |
| Olapar | 100 mg | Tablet |
| Olapar | 150 mg | Tablet |
Osimertinib Cancer (oncology)
Originator: Tagrisso · AstraZeneca
| Brand | Strength | Form |
|---|---|---|
| Ositag | 80 mg tablet | — |
| Ositag | 80 mg | Tablet |
Palbociclib Cancer (oncology)
Originator: Ibrance · Pfizer Inc. (Pfizer Laboratories Div Pfizer Inc)
| Brand | Strength | Form |
|---|---|---|
| Palker (exported/marketed as Palbonix) | 125 mg capsule | — |
| Palker | 125 mg | Capsule |
Rituximab Cancer (oncology)
Originator: Rituxan · Genentech, Inc. (a member of the Roche Group), with Biogen; Rituxan is jointly marketed by Biogen and Genentech USA in the US; MabThera is marketed by Roche
| Brand | Strength | Form |
|---|---|---|
| Rituxim | 10 mg/mL, 100 mg and 500 mg vials | — |
| Rituxim | 10 mg/ml | IV Infusion |
Sofosbuvir/Velpatasvir Antivirals (hepatitis C)
Originator: Epclusa · Gilead Sciences (Gilead Sciences Ireland UC for the EU)
| Brand | Strength | Form |
|---|---|---|
| Fixvel; Sofosvel | 400 mg + 100 mg tablet | — |
| Fixvel | 400 mg+100 mg | Tablet |
Tofacitinib Immunology & rheumatology
Originator: Xeljanz / Xeljanz XR · Pfizer (initial U.S. approval 2012)
| Brand | Strength | Form |
|---|---|---|
| Jaktor | 5 mg | Tablet |
| Jaktor XR | 11 mg | Tablet (Extended Release) |
| Tofacinix | 11 mg | Tablet (Extended Release) |
Trastuzumab Cancer (oncology)
Originator: Herceptin · Genentech, Inc. / F. Hoffmann-La Roche Ltd
| Brand | Strength | Form |
|---|---|---|
| Trastunix | 440 mg/20 mL | — |
| Trastunix | 440 mg/20 ml | IV Infusion |
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.
